Never miss a story

Get subscribed to our newsletter


×
Cancer immunotherapies, which empower patients' immune systems to eliminate tumors, are revolutionizing cancer treatment. Unsplash

In a new clinical trial, a drug-induced an integrated immune response in the tumors of patients with cancer types that do not usually respond to immunotherapy, say, researchers.

According to the study, published in the journal Proceedings of the National Academy of Sciences, the team hopes the potential treatment might make such tumors more responsive to the class of drugs known as immune checkpoint inhibitors.


Follow NewsGram on Instagram to keep yourself updated.

“Checkpoint inhibitors release natural brakes on the immune system, freeing it to find and destroy cancer cells. But they generally have not been effective against cancer cells with low levels of genetic mutation,” said study author Tobias Janowitz from the University of Cambridge in the UK.

Cancer immunotherapies, which empower patients’ immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions.

Follow NewsGram on Twitter to stay updated about the World news.

But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.


All patients had advanced disease, and biopsies were collected from metastatic tumors before and after treatment. Pixabay

In this clinical trial, the research team interrupted that immunosuppressive pathway with a drug called plerixafor.

The drug was administered continuously by intravenous therapy (IV) for one week to 24 patients with either pancreatic cancer or colorectal cancer with a low tumor mutational burden.

Want to read more in Hindi? Checkout: ‘स्कैम 1992’ के लिए डायलॉग लिखना क्यों था चुनौतीपूर्ण?

All patients had advanced disease, and biopsies were collected from metastatic tumors before and after treatment.

When the team analyzed those patient samples, they found that critical immune cells had infiltrated the tumors during the time patients received plerixafor, including a cell type known to summon and organize key players in the anti-cancer response.

Also Read: Covid-19 Disproportionately Affecting People With Obesity

The finding was encouraging because the team detected changes that have also been observed in patients whose cancers responded well to checkpoint inhibitors, the authors wrote. (IANS)


Popular

Photo by Alexander Shatov on Unsplash

Twitter has confirmed that its algorithms amplify right-leaning political content.

By Nikhila Natarajan

In a continuing study on the effects of machine learning (ML) on public conversation, Twitter has confirmed that its algorithms amplify right-leaning political content. "In six out of seven countries - all but Germany - tweets posted by accounts from the political right receive more algorithmic amplification than the political left when studied as a group," Twitter blogged.

"Right-leaning news outlets, as defined by the independent organisations, see greater algorithmic amplification on Twitter compared to left-leaning news outlets." Since 2016, Twitter users are able to choose between viewing algorithmically ordered tweets first in their home timeline or viewing the most recent tweets in reverse chronological order.

"An algorithmic home timeline displays a stream of tweets from accounts we have chosen to follow on Twitter, as well as recommendations of other content Twitter thinks we might be interested in based on accounts we interact with frequently, tweets we engage with, and more. "As a result, what we see on our timeline is a function of how we interact with Twitter's algorithmic system, as well as how the system is designed."

The new research is based on tweets of elected officials of House of Commons members in Canada, the French National Assembly, the German Bundestag, House of Representatives in Japan, Congress of Deputies of Spain, House of Commons in the UK, and official and personal accounts of House of Representatives and Senate members in the US, as well as news outlets, from April 1 to August 15, 2020.

gold Apple iPhone 6s displaying Twitter logo Tweets about political content from elected officials, regardless of party or whether the party is in power, do see algorithmic amplification when compared to political content on the reverse chronological timeline. | Photo by Sara Kurfeß on Unsplash

Keep Reading Show less
Flickr

Snapdeal co-founder and COO Rohit Bansal on Friday lauded a man who facilitated 64 registrations for the vaccine on the CoWin portal.

Even as India celebrates reaching a milestone of 100 crore Covid vaccine doses, Snapdeal co-founder and COO Rohit Bansal on Friday lauded a man who facilitated 64 registrations for the vaccine on the CoWin portal. In a video shared on his Facebook and Twitter page, Bansal hailed Sonu Kumar as a "citizen celebrity".

Bansal said that Kumar not only helped "just co-workers and family but complete strangers too. With patience, empathy and uncanny jugaad". He added that Kumar joined him "many moons ago" and completed his open school from a parking lot.

"Education has helped this wonderful man enable others to get India back on track. Bravo! The CoWin portal on Thursday mentioned that a total of 100 crore vaccine doses has been administered so far to the eligible population under the vaccination drive in India, nine months after the nationwide inoculation programme was started to protect the people against Covid-19.

"It's a cause of significant celebration and happiness," Bansal said in the video. He said that while people just help a few around them, Kumar "bridged the digital gap" for 64 people, who were finding it difficult to register themselves online on the vaccine portal. Kumar said he doesn't feel that he has contributed much towards the 100 crore vaccine dose count. "I have been able to help only 64 people, if I was able to help more I would have been happier." (IANS/ MBI)


Keep Reading Show less
VOA

A health worker counts antiretroviral drug tablets for a patient at The AIDS Support Organization (TASO) in the capital Kampala, Uganda, July 12, 2012.

KAMPALA, UGANDA — Uganda has kickstarted a trial for the injectable HIV drugs cabotegravir and rilpivirine. Researchers and those living with HIV say the trial will likely end pill fatigue, fight stigma, improve adherence and ensure patients get the right dosage.

The two drugs have been in use as tablets. The World Health Organization last year licensed their use as injectables.

Keep reading... Show less